Windtree Therapeutics, Inc. Revenue

Revenue of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue growth rates and interactive chart. Revenue is the income generated from normal business operations and includes discounts and deductions for returned merchandise. It is the top line or gross income figure from which costs are subtracted to determine net income.


Highlights and Quick Summary

  • Revenue for the quarter ending December 30, 2019 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Revenue decreased by -100.0%
  • Annual Revenue for 2019 was $198 Thousand (a -88.93% decrease from previous year)
  • Annual Revenue for 2018 was $1.79 Million (a 20.4% increase from previous year)
  • Annual Revenue for 2017 was $1.49 Million (a -27.28% decrease from previous year)
  • Twelve month Revenue ending December 30, 2019 was $502 Thousand (a -31.33% decrease compared to previous quarter)
  • Twelve month trailing Revenue decreased by -71.92% year-over-year
Trailing Revenue for the last four month:
30 Dec '19 29 Jun '19 30 Mar '19 30 Dec '18
$502 Thousand $731 Thousand $1.62 Million $1.79 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue of Windtree Therapeutics, Inc.

Most recent Revenueof WINT including historical data for past 10 years.

Interactive Chart of Revenue of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.0 $0.16 $0.04 $0.2
2018 $0.3 $0.23 $1.05 $0.2 $1.79
2017 $0.1 $0.02 $1.15 $0.22 $1.49
2016 $0.9 $0.96 $0.11 $0.08 $2.04
2015 $0.66 $0.07 $0.08 $0.19 $0.99
2014 $1.18 $0.53 $1.09 $0.03 $2.84
2013 $0.07 $0.06 $0.18 $0.07 $0.39
2012 $0.2
2011 $0.2 $0.38 $0.58

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.